ANI Pharmaceuticals
 
1Q Revenues: $18.8 million (+72%)

1Q Earnings: $4.4 million (+30%)

Comments: Generic sales were up 52% to $12.3 million primarily due to increased sales of EEMT, as well as Methazolamide and Etodolac products, which launched in 4Q14 and 1Q15, respectively. Branded pharmaceutical sales increased 452% to $4.3 million, driven by sales of Lithobid and Vancocin, which were acquired in 3Q14. Contract manufacturing revenue was down 26% to $1.2 million as a result of timing of customer orders. Contract services and other revenues increased 136% to $1.1 million due to royalties from the authorized generic of Vancocin.